National Institute on Drug Abuse; Notice of Meeting, 81952 [2011-33489]
Download as PDF
<![CDATA[
81952
Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices
Dated: December 22, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2011–33492 Filed 12–28–11; 8:45 am]
National Institute on Drug Abuse;
Notice of Meeting
National Institutes of Health
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
wreier-aviles on DSK3TPTVN1PROD with NOTICES
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel,
Training and Career Development
Subcommittee.
Date: March 6–7, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Eliane Lazar-Wesley,
Ph.D., Health Scientist Administrator, Office
of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, Room 4245, MSC
9550, 6001 Executive Blvd., Bethesda, MD
20892–9550, (301) 451–4530, el6r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 22, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–33491 Filed 12–28–11; 8:45 am]
BILLING CODE 4140–01–P
VerDate Mar<15>2010
15:12 Dec 28, 2011
Jkt 226001
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Council on Drug
Abuse.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council on Drug Abuse.
Date: February 14–15, 2012.
Closed: February 14, 2012, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Conference Rooms C & D,
Rockville, MD 20852.
Open: February 15, 2012, 8:30 a.m. to
1 p.m.
Agenda: This portion of the meeting will
be open to the public for announcements and
reports of administrative, legislative and
program developments in the drug abuse
field.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Conference Rooms C & D,
Rockville, MD 20852.
Contact Person: Teresa Levitin, Ph.D.,
Director, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 4243, MSC 9550, 6001
Executive Boulevard, Bethesda, MD 20892–
89550, (301) 443–2755, tlevitin.nida.nih.gov.
Any member of the public interested in
presenting oral comments to the committee
may notify the Contact Person listed on this
notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations may submit
a letter of intent, a brief description of the
organization represented, and a short
description of the oral presentation. Only one
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
representative of an organization may be
allowed to present oral comments and if
accepted by the committee, presentations
may be limited to five minutes. Both printed
and electronic copies are requested for the
record. In addition, any interested person
may file written comments with the
committee by forwarding their statement to
the Contact Person listed on this notice. The
statement should include the name, address,
telephone number and when applicable, the
business or professional affiliation of the
interested person.
Information is also available on the
Institute’s/Center’s home page:
www.drugabuse.gov/NACDA/
NACDAHome.html, where an agenda and
any additional information for the meeting
will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: December 22, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–33489 Filed 12–28–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel, P01 Special
Emphasis Panel Three.
Date: January 24–25, 2012.
Time: 8 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville, 1750
Rockville Pike, Rockville, MD 20852.
Contact Person: Majed M. Hamawy, PhD.,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramual
Activities, National Cancer Institute, NIH,
6116 Executive Boulevard, Room 8135,
Bethesda, MD 20892, (301) 594–5659,
mh101v@nih.gov.
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 76, Number 250 (Thursday, December 29, 2011)]
[Notices]
[Page 81952]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33489]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of a meeting of the
National Advisory Council on Drug Abuse.
The meeting will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Council on Drug Abuse.
Date: February 14-15, 2012.
Closed: February 14, 2012, 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Conference Rooms C & D, Rockville, MD 20852.
Open: February 15, 2012, 8:30 a.m. to 1 p.m.
Agenda: This portion of the meeting will be open to the public
for announcements and reports of administrative, legislative and
program developments in the drug abuse field.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Conference Rooms C & D, Rockville, MD 20852.
Contact Person: Teresa Levitin, Ph.D., Director, Office of
Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS,
Room 4243, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892-
89550, (301) 443-2755, tlevitin.nida.nih.gov.
Any member of the public interested in presenting oral comments
to the committee may notify the Contact Person listed on this notice
at least 10 days in advance of the meeting. Interested individuals
and representatives of organizations may submit a letter of intent,
a brief description of the organization represented, and a short
description of the oral presentation. Only one representative of an
organization may be allowed to present oral comments and if accepted
by the committee, presentations may be limited to five minutes. Both
printed and electronic copies are requested for the record. In
addition, any interested person may file written comments with the
committee by forwarding their statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and
any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: December 22, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-33489 Filed 12-28-11; 8:45 am]
BILLING CODE 4140-01-P
